Evidence map›Paper›PMID 38755790›Full record

ArticleInvestigative ophthalmology & visual science2020

Acylcarnitine Abnormalities Implicate Mitochondrial Dysfunction in Patients With Neovascular Age-Related Macular Degeneration.

Gerald Liew, Benita Tse, I-Van Ho, Nichole Joachim, Andrew White, Russell Pickford, David Maltby, Bamini Gopinath, Paul Mitchell, Ben Crossett

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Investigative ophthalmology & visual science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Gerald LiewCentre for Vision Research, Department of Ophthalmology (Westmead Hospital), Westmead Institute for Medical Research, University of Sydney, Sydney, Australia.
Benita TseCharles Perkins Centre, University of Sydney, Sydney, Australia.
I-Van HoRetina Associates, Sydney, Australia.
Nichole JoachimCentre for Vision Research, Department of Ophthalmology (Westmead Hospital), Westmead Institute for Medical Research, University of Sydney, Sydney, Australia.
Andrew WhiteCentre for Vision Research, Department of Ophthalmology (Westmead Hospital), Westmead Institute for Medical Research, University of Sydney, Sydney, Australia.
Russell PickfordBioanalytical Mass Spectrometry Facility, University of New South Wales, Kensington, Australia.
David MaltbySydney Mass Spectrometry, University of Sydney, Sydney, Australia.
Bamini GopinathCentre for Vision Research, Department of Ophthalmology (Westmead Hospital), Westmead Institute for Medical Research, University of Sydney, Sydney, Australia.
Paul MitchellCentre for Vision Research, Department of Ophthalmology (Westmead Hospital), Westmead Institute for Medical Research, University of Sydney, Sydney, Australia.
Ben CrossettSydney Mass Spectrometry, University of Sydney, Sydney, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Abnormalities in lipid metabolism are implicated in age-related macular degeneration (AMD), but the pathways involved remain unclear. We assessed whether acylcarnitine concentrations, a marker of lipid and mitochondrial metabolism, differed between patients with AMD and controls. Methods: In this cross-sectional case-control study, cases (n = 81) had neovascular AMD and controls (n = 79) had cataract with no other ocular pathology. Participants were recruited from eye clinics in Western Sydney, Australia, between 2016 and 2018. Plasma blood samples were collected and liquid chromatography mass spectrometry analyses performed to identify acylcarnitine concentrations. Acylcarnitine levels were adjusted for age, gender and smoking in multivariable models. Confirmation of key acylcarnitine identities was conducted using high mass accuracy liquid chromatography-tandem mass spectrometry. Results: After multivariable adjustment, C2-carnitine (acetylcarnitine) levels were significantly lower in patients with neovascular AMD compared to controls (0.810 ± 0.053 (standard error) compared to 1.060 ± 0.053), p = 0.002). C18:2-DC carnitine (a dicarboxylic acylcarnitine with a 18 carbon side chain and 2 double bonds), levels were significantly higher in patients with neovascular AMD compared to controls (1.244 ± 0.046 compared to 1.013 ± 0.046), p = 0.001). Other acylcarnitines examined were not significantly different between cases and controls. Conclusions: Reduced plasma levels of C2-carnitine (acetylcarnitine) and increased plasma levels of C18:2-DC carnitine were observed in patients with neovascular AMD compared to controls. These findings suggest mitochondrial dysfunction could be involved in the pathogenesis of neovascular AMD.

Identifiers

PMID38755790
PMCPMC7425723

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.